Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Fasching, P; Stechemesser, L; Auer, J; Clodi, M; Gattringer, T; Niessner, A; Perl, S; Saemann, M; Seinost, G; Huber, K.
Practical realization of guidelines for treatment of type 2 diabetes with a high cardiovascular risk
J KARDIOL. 2023; 30(5-6): 119-122.
Web of Science

 

Führende Autor*innen der Med Uni Graz
Fasching Patrizia
Co-Autor*innen der Med Uni Graz
Gattringer Thomas
Perl Sabine
Seinost Gerald
Altmetrics:

Abstract:
In recent years, GLP-1 receptor-agonists and SGLT2 inhibitors have shown a very high level of evidence and recommendation for the treatment of patients with type-2-diabetes and high cardiovascular risk. These medications were developed for the treatment of hyperglycemia, cardiovascular endpoint studies showed a CV-benefit independent of baseline-HbA1c. In the practical im-plementation of these therapies, however, there are ongoing challenges that need to be identified and overcome - especially for this well described high risk population. J Kardiol 2023; 30 (5-6): 119-22.

Find related publications in this database (Keywords)
type-2-diabetes
high cardiovascular risk
guidelines
GLP-1 Receptor-Agonists
SGLT2 In-hibitors
CV-benefit
© Med Uni Graz • Impressum